An article on the effectiveness of the ZF-UZ-VAC2001 vaccine was published in The New England Journal of Medicine

Tashkent, Uzbekistan (UzDaily.com) -- The results of phase 3 trials of the ZF-UZ-VAC2001 vaccine, developed in collaboration with Uzbek and Chinese scientists, in Uzbekistan and other countries were published in one of the most prestigious medical journals - The New England Journal of Medicine (NEJM).

The article was co-authored with Uzbek and Chinese scientists and is devoted to the results of a placebo-controlled study conducted to study the efficacy and safety of the ZF-UZ-VAC2001 vaccine.

The Phase 3 study of the ZF-UZ-VAC2001 vaccine was conducted at 31 clinical centers in Uzbekistan, China, Indonesia, Pakistan and Ecuador with about 29,000 volunteers. Participants in this trial received the vaccine or placebo in a 1:1 ratio. A total of 158 cases of COVID-19 infection were reported in the group of 12,625 vaccinated volunteers, as well as 580 cases of COVID-19 in a group of 12,568 placebo volunteers. As a result, the effectiveness of the vaccine was 75.7%. In addition, the effectiveness of the vaccine against severe and very severe forms of COVID-19 disease and deaths was 87.6% and 86.5%, respectively.

About 98.5% of side effects were found to be grade 1 or 2. In turn, no vaccine-related deaths have been reported. The article notes that the ZF2001 vaccine is effective and safe in the prevention of asymptomatic, severe and very severe forms of COVID-19 disease. Thus, the ZF-UZ-VAC2001 vaccine prevents infection with symptomatic and acute forms of coronavirus for at least six months after full vaccination.

It should be noted that NEJM is one of the most prestigious journals in the field of medicine and has been published since 1812. The journal has an impact factor (IF) of 91 in the ranking of scientific journals in 2021 and is among the top three scientific journals: 1st place is the CA-A Cancer Journal for Clinicians (IF = 508.7); 2nd place "Nature Review Molecular Cell Biology" (IF = 94.4): 3rd place NEJM (IF = 91.2); 4th place "Nature Reviews Drug Discovery" (IF = 84.7); On the 5th place is Lancet (IF=79.3). NEJM is distributed in 175 countries worldwide.